Lutikizumab

DB16224InvestigationalProtein Based Therapies

Lutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).

Mechanism: Pharmacologically active on Interleukin-1 alpha and Interleukin-1 beta
Curator reviewed
Also known as: Immunoglobulin, anti-(interleukin 1.beta./interleukin 1.alpha.) (synthetic human a-1234138 heavy chain), disulfide with synthetic human a-1234138 light chain, dimer
Code names: A-1234138 · ABT-981

Resolves to

Compound

UNII15FAZ725S0CAS1791411-57-8

Targets

P01583IL1AP01584IL1B

What you can answer from here — as of May 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lutikizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account